All filters
Slidesets
Evidence Supporting Liver Targeting of Tenofovir Exalidex (TXL)- Dr. R. Foster
Presented at:
HEP DART 2017
Slidesets
Validation of a novel Transient Elastography for the measurement of liver fibrosis- Dr. J. Dong
Presented at:
HEP DART 2017
Slidesets
Strategy for the Elimination of Hepatitis B and C (Academy of Medicine Report)- Andrew Aronsohn, MD
Presented at:
HEP DART 2017
Slidesets
Eliminating Hepatitis C by 2030 - Enhancing prevention care and treatment among people who inject drugs- Margaret Hellard, AM, MBBS, FRACP, FAFPHM, PhD
Presented at:
HEP DART 2017
Slidesets
Consensus AASLD-EASL HBV Treatment Endpoint and HBV Cure Definition- Anna S. Lok, MD, DSc
Presented at:
HEP DART 2017
Slidesets
Global Strategies to Eliminate Hepatitis B (ICE-HBV)- Peter Revill
Presented at:
HEP DART 2017
Slidesets
The French and European Approach Towards Hepatitis Elimination- Tarik Asselah, MD, PhD
Presented at:
HEP DART 2017
Slidesets
Access to HIV, HBV, and HCV Antiviral Agents Globally- John Martin, PhD
Presented at:
HEP DART 2017
Slidesets
DAA Therapy and Reinfection Among People who Inject Drugs: Forming a Foundation for HCV Elimination- Jason Grebely
Presented at:
HEP DART 2017
Slidesets
Liver Disease in Chinese-perspective from a Hepatologist- George Lau, MBBS, MRCP, FHKCP, FHKAM, MD, FRCP
Presented at:
HEP DART 2017
Slidesets
A Tale of Two Viruses: HBV and HCV Co-infection (not available)- Jake Liang
Presented at:
HEP DART 2017
Slidesets
The Global Burden of Non-alcoholic Steatohepatitis (not available)- Zobair Younossi
Presented at:
HEP DART 2017
Slidesets
Short Duration DAA HCV Therapy: How Short Can We Go?- Shyam Kottilil, MD, PhD
Presented at:
HEP DART 2017
Slidesets
Hepatitis B/C and NASH: Crossroads Between Science and Business (not available)- Geoffrey Meacham
Presented at:
HEP DART 2017
Slidesets
Catch me if you can – tuning immunity for HBV cure (not available)- Ulrike Protzer, MD
Presented at:
HEP DART 2017